Literature DB >> 18640965

Mechanism of the Ca2+-induced enhancement of the intrinsic factor VIIa activity.

Jais R Bjelke1, Ole H Olsen, Michel Fodje, L Anders Svensson, Susanne Bang, Gert Bolt, Birthe B Kragelund, Egon Persson.   

Abstract

The intrinsic activity of coagulation factor VIIa (FVIIa) is dependent on Ca(2+) binding to a loop (residues 210-220) in the protease domain. Structural analysis revealed that Ca(2+) may enhance the activity by attenuating electrostatic repulsion of Glu(296) and/or by facilitating interactions between the loop and Lys(161) in the N-terminal tail. In support of the first mechanism, the mutations E296V and D212N resulted in similar, about 2-fold, enhancements of the amidolytic activity. Moreover, mutation of the Lys(161)-interactive residue Asp(217) or Asp(219) to Ala reduced the amidolytic activity by 40-50%, whereas the K161A mutation resulted in 80% reduction. Hence one of these Asp residues in the Ca(2+)-binding loop appears to suffice for some residual interaction with Lys(161), whereas the more severe effect upon replacement of Lys(161) is due to abrogation of the interaction with the N-terminal tail. However, Ca(2+) attenuation of the repulsion between Asp(212) and Glu(296) keeps the activity above that of apoFVIIa. Altogether, our data suggest that repulsion involving Asp(212) in the Ca(2+)-binding loop suppresses FVIIa activity and that optimal activity requires a favorable interaction between the Ca(2+)-binding loop and the N-terminal tail. Crystal structures of tissue factor-bound FVIIa(D212N) and FVIIa(V158D/E296V/M298Q) revealed altered hydrogen bond networks, resembling those in factor Xa and thrombin, after introduction of the D212N and E296V mutations plausibly responsible for tethering the N-terminal tail to the activation domain. The charge repulsion between the Ca(2+)-binding loop and the activation domain appeared to be either relieved by charge removal and new hydrogen bonds (D212N) or abolished (E296V). We propose that Ca(2+) stimulates the intrinsic FVIIa activity by a combination of charge neutralization and loop stabilization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640965      PMCID: PMC3258868          DOI: 10.1074/jbc.M800841200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Allosteric activation of coagulation factor VIIa visualized by hydrogen exchange.

Authors:  Kasper D Rand; Thomas J D Jørgensen; Ole H Olsen; Egon Persson; Ole N Jensen; Henning R Stennicke; Mette D Andersen
Journal:  J Biol Chem       Date:  2006-05-10       Impact factor: 5.157

Review 2.  Roles of platelets and factor XI in the initiation of blood coagulation by thrombin.

Authors:  P N Walsh
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

3.  Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.

Authors:  L V Rao; S I Rapaport; A D Hoang
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

4.  Structural changes in factor VIIa induced by Ca2+ and tissue factor studied using circular dichroism spectroscopy.

Authors:  P O Freskgård; O H Olsen; E Persson
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

5.  Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes.

Authors:  Egon Persson; Ole H Olsen
Journal:  Eur J Biochem       Date:  2002-12

6.  Identification of a calcium binding site in the protease domain of human blood coagulation factor VII: evidence for its role in factor VII-tissue factor interaction.

Authors:  P Wildgoose; D Foster; J Schiødt; F C Wiberg; J J Birktoft; L C Petersen
Journal:  Biochemistry       Date:  1993-01-12       Impact factor: 3.162

7.  Complex-dependent inhibition of factor VIIa by antithrombin III and heparin.

Authors:  J H Lawson; S Butenas; N Ribarik; K G Mann
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

8.  The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.

Authors:  V J Bom; R M Bertina
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

9.  High affinity Ca(2+)-binding site in the serine protease domain of human factor VIIa and its role in tissue factor binding and development of catalytic activity.

Authors:  A K Sabharwal; J J Birktoft; J Gorka; P Wildgoose; L C Petersen; S P Bajaj
Journal:  J Biol Chem       Date:  1995-06-30       Impact factor: 5.157

10.  The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro.

Authors:  J Torbet
Journal:  Thromb Haemost       Date:  1995-05       Impact factor: 5.249

View more
  4 in total

1.  Sites involved in intra- and interdomain allostery associated with the activation of factor VIIa pinpointed by hydrogen-deuterium exchange and electron transfer dissociation mass spectrometry.

Authors:  Hongjian Song; Ole H Olsen; Egon Persson; Kasper D Rand
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

2.  Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2.

Authors:  Katrine S Larsen; Henrik Ostergaard; Ole H Olsen; Jais R Bjelke; Wolfram Ruf; Lars C Petersen
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

3.  Structural and functional studies of γ-carboxyglutamic acid domains of factor VIIa and activated Protein C: role of magnesium at physiological calcium.

Authors:  Kanagasabai Vadivel; Sayeh Agah; Amanda S Messer; Duilio Cascio; Madhu S Bajaj; Sriram Krishnaswamy; Charles T Esmon; Kaillathe Padmanabhan; S Paul Bajaj
Journal:  J Mol Biol       Date:  2013-02-20       Impact factor: 5.469

4.  Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation.

Authors:  Tobias Kromann-Hansen; Eva Louise Lange; Ida K Lund; Gunilla Høyer-Hansen; Peter A Andreasen; Elizabeth A Komives
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.